UA49004C2 - Таблетка з уповільненим вивільненням, що містить мізоластин - Google Patents

Таблетка з уповільненим вивільненням, що містить мізоластин

Info

Publication number
UA49004C2
UA49004C2 UA98084447A UA98084447A UA49004C2 UA 49004 C2 UA49004 C2 UA 49004C2 UA 98084447 A UA98084447 A UA 98084447A UA 98084447 A UA98084447 A UA 98084447A UA 49004 C2 UA49004 C2 UA 49004C2
Authority
UA
Ukraine
Prior art keywords
mizolastin
slow
pharmaceutical formulations
formulations containing
release pharmaceutical
Prior art date
Application number
UA98084447A
Other languages
English (en)
Russian (ru)
Inventor
Марівонн ШАРІО
Ґерет ЛЮІС
Жан Монтель
Original Assignee
Санофі-Сентелябо
Санофи-Сентелябо
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофі-Сентелябо, Санофи-Сентелябо filed Critical Санофі-Сентелябо
Publication of UA49004C2 publication Critical patent/UA49004C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Розкрито фармацевтичну композицію з уповільненим вивільненням мізоластину, яка характеризується тим, що включає серцевину, утворену таблеткою з уповільненим вивільненням, що включає мізоластин у поєднанні з жировою матрицею та органічною кислотою, та покриття вказаної таблетки.
UA98084447A 1996-03-04 1997-02-28 Таблетка з уповільненим вивільненням, що містить мізоластин UA49004C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
PCT/FR1997/000355 WO1997032584A1 (fr) 1996-03-04 1997-02-28 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine

Publications (1)

Publication Number Publication Date
UA49004C2 true UA49004C2 (uk) 2002-09-16

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98084447A UA49004C2 (uk) 1996-03-04 1997-02-28 Таблетка з уповільненим вивільненням, що містить мізоластин

Country Status (35)

Country Link
US (2) US6165507A (uk)
EP (1) EP0906101B1 (uk)
JP (2) JP2000512617A (uk)
KR (1) KR100369888B1 (uk)
CN (1) CN1112929C (uk)
AR (1) AR006082A1 (uk)
AT (1) ATE219365T1 (uk)
AU (1) AU725494B2 (uk)
BG (1) BG63451B1 (uk)
BR (1) BR9707827A (uk)
CA (1) CA2247405C (uk)
CO (1) CO4780020A1 (uk)
CY (1) CY2293B1 (uk)
CZ (1) CZ291418B6 (uk)
DE (1) DE69713505T2 (uk)
DK (1) DK0906101T3 (uk)
EE (1) EE03511B1 (uk)
ES (1) ES2177942T3 (uk)
FR (1) FR2745500B1 (uk)
HK (1) HK1017999A1 (uk)
HU (1) HU227472B1 (uk)
IL (1) IL126050A (uk)
IN (1) IN187739B (uk)
NO (1) NO315841B1 (uk)
NZ (1) NZ331947A (uk)
OA (1) OA10854A (uk)
PL (1) PL189813B1 (uk)
PT (1) PT906101E (uk)
RU (1) RU2173997C2 (uk)
SK (1) SK282112B6 (uk)
TR (1) TR199801574T2 (uk)
TW (1) TW491711B (uk)
UA (1) UA49004C2 (uk)
WO (1) WO1997032584A1 (uk)
ZA (1) ZA971830B (uk)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10101564A (ja) * 1996-09-27 1998-04-21 Mitsubishi Chem Corp 鼻炎予防及び/又は治療剤
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
EP1322158B1 (en) * 2000-10-02 2012-08-08 USV Ltd. Sustained release pharmaceutical compositions containing metformin and method of their production
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
BR0318167A (pt) * 2003-03-04 2006-02-21 Nostrum Pharmaceuticals Inc formulação de liberação controlada contendo um material hidrofóbico como o agente de liberação controlada
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
UY32008A (es) 2008-07-28 2010-02-26 Takeda Pharmaceutical Composición farmacéutica
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Also Published As

Publication number Publication date
ZA971830B (en) 1997-09-04
AU725494B2 (en) 2000-10-12
AR006082A1 (es) 1999-08-11
AU1930097A (en) 1997-09-22
KR100369888B1 (ko) 2003-05-17
SK121098A3 (en) 1999-01-11
CA2247405A1 (en) 1997-09-12
IL126050A (en) 2004-05-12
PT906101E (pt) 2002-09-30
NO984035L (no) 1998-10-22
HUP9902458A2 (hu) 2000-05-28
CZ291418B6 (cs) 2003-03-12
BG102692A (en) 1999-04-30
EP0906101B1 (fr) 2002-06-19
US6165507A (en) 2000-12-26
CN1112929C (zh) 2003-07-02
DK0906101T3 (da) 2002-10-14
NZ331947A (en) 2000-03-27
EE9800275A (et) 1999-02-15
JP2000512617A (ja) 2000-09-26
CA2247405C (en) 2004-04-20
SK282112B6 (sk) 2001-11-06
KR19990087387A (ko) 1999-12-27
BR9707827A (pt) 1999-07-27
NO984035D0 (no) 1998-09-02
EP0906101A1 (fr) 1999-04-07
IL126050A0 (en) 1999-05-09
BG63451B1 (bg) 2002-02-28
NO315841B1 (no) 2003-11-03
CN1212624A (zh) 1999-03-31
DE69713505T2 (de) 2003-02-13
TR199801574T2 (xx) 1998-11-23
TW491711B (en) 2002-06-21
CO4780020A1 (es) 1999-05-26
HU227472B1 (en) 2011-07-28
CZ279198A3 (cs) 1999-01-13
ATE219365T1 (de) 2002-07-15
FR2745500A1 (fr) 1997-09-05
DE69713505D1 (de) 2002-07-25
RU2173997C2 (ru) 2001-09-27
EE03511B1 (et) 2001-10-15
OA10854A (fr) 2003-02-05
HK1017999A1 (en) 1999-12-10
JP2007182451A (ja) 2007-07-19
ES2177942T3 (es) 2002-12-16
HUP9902458A3 (en) 2002-11-28
PL328763A1 (en) 1999-02-15
FR2745500B1 (fr) 1998-04-03
WO1997032584A1 (fr) 1997-09-12
PL189813B1 (pl) 2005-09-30
US20050202089A1 (en) 2005-09-15
CY2293B1 (en) 2003-07-04
IN187739B (uk) 2002-06-15

Similar Documents

Publication Publication Date Title
AU4380896A (en) Pharmaceutical composition containing fenofibrate and polyglycolized glycerides
ES2141380T3 (es) Metodo para la fabricacion de un comprimido recubierto, con nucleo puntiagudo.
CA2203652A1 (en) A method of down-regulating gene expression
HUP0000145A3 (en) Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them
AU2455497A (en) Method and apparatus for scheduling the presentation of messages to computer users
PT973413E (pt) Formulacoes nutricionais que contem lacto-n-neotetraose
TWI235068B (en) Sustained-release pharmaceutical composition
CA2184433A1 (en) Retinoid Formulations in Porous Microspheres for Reduced Irritation and Enhanced Stability
UA49004C2 (uk) Таблетка з уповільненим вивільненням, що містить мізоластин
GR3035382T3 (en) Active substance combinations comprising pyrethroids and insect-development inhibitors
MY104412A (en) Acne treatment.
GEP20043198B (en) Extended Release Formulation
IT1265074B1 (it) Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
RS49602B (sr) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
AU6642994A (en) Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
AU5395794A (en) 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1- carboxamide as an analgesic and anti-inflammatory agent
AU4519399A (en) Anti-inflammatory pharmaceutical formulations
AU3096992A (en) Environment-friendly and energy saving animal stable for instance for pigs
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
PL325343A1 (en) Method of cell-free in vitro transcribing a dna matrix, dna matrix a such and application of that method and such dna matrix
ES2193514T3 (es) Utilizacion de combinaciones de sustancias activas a base de antibioticos y de estractos vegetales que contienen terpenos en la medicina veterinaria.
AU5647096A (en) Combined preparations with vascular effect containing dihydr opyridines, acetylsalicylic acid nitroesters and vitamins
AP2000001728A0 (en) Novel composition.
EP0618232A3 (en) Compound BS-3, an antioxidant for fats and analgesic.